Cut-offs for relapse detection in men with stage I testicular germ cell tumors during active surveillance within a prospective multicentre cohort study using either raw or housekeeper normalized miR-371a-3p serum levels

Our preliminary data suggest that this CE-certified assay, using previously suggested cut-off values, is a promising method for detecting disease recurrence, provided a confirmatory second test is conducted to identify false positive results. To avoid unnecessary scans or overtreatment, we are currently validating this assay and cut-offs in a prospective cohort study.

Authors

Institutions

Publication Details

Journal
Urologic Oncology Seminars and Original Investigations
Published
2024-09-10
DOI
https://doi.org/10.1016/j.urolonc.2024.07.013
Citations
1
Primary Topic
Testicular diseases and treatments
Type
article
Field-Weighted Citation Impact
0.57
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Cut-offs for relapse detection in men with stage I testicular germ cell tumors during active surveillance within a prospective multicentre cohort study using either raw or housekeeper normalized miR-371a-3p serum levels

Silke Gillessen, J. Beyer, Ernest Kaufmann, Christian D. Fankhauser et al.
1 citations
Urologic Oncology Seminars and Original Investigations
Testicular diseases and treatments
0.57
article

Cut-offs for relapse detection in men with stage I testicular germ cell tumors during active surveillance within a prospective multicentre cohort study using either raw or housekeeper normalized miR-371a-3p serum levels

Silke Gillessen, J. Beyer, Ernest Kaufmann, Christian D. Fankhauser, Ailsa J. Christiansen, Anja Lorch, Christian Rothermundt, Arnoud J. Templeton, Richard Cathomas, Thomas Hermanns, Anita Hirschi-Blickenstorfer, Silvan Sigg, Marian S. Wettstein
article en
1 citations

Abstract

Our preliminary data suggest that this CE-certified assay, using previously suggested cut-off values, is a promising method for detecting disease recurrence, provided a confirmatory second test is conducted to identify false positive results. To avoid unnecessary scans or overtreatment, we are currently validating this assay and cut-offs in a prospective cohort study.

Urologic Oncology Seminars and Original InvestigationsVol. 42(12)
University of Lucerne (CH), University of Basel (CH), University of Zurich (CH), Kantonsspital St. Gallen (CH), University Hospital of Bern (CH), Klinik Hirslanden (CH), University Hospital of Zurich (CH), Institute of Oncology Research (CH), Luzerner Kantonsspital (CH), Center for Pediatric Endocrinology Zurich (CH), St. Claraspital (CH), Kantonsspital Graubünden (CH), GastroZentrum Hirslanden Zürich (CH), Immunologie-Zentrum Zürich (CH), Università della Svizzera italiana (CH)
Gender equality
Openalex Percentile: Top 30%
Testicular diseases and treatments
0.57
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.